Literature DB >> 20484585

Retinal disease in Rpe65-deficient mice: comparison to human leber congenital amaurosis due to RPE65 mutations.

Rafael C Caruso1, Tomas S Aleman, Artur V Cideciyan, Alejandro J Roman, Alexander Sumaroka, Cristina L Mullins, Sanford L Boye, William W Hauswirth, Samuel G Jacobson.   

Abstract

PURPOSE: To quantify the retinal disease in Rpe65-deficient mice across a wide age span and compare the results to those in humans with Leber congenital amaurosis (LCA) caused by RPE65 mutations.
METHODS: Full-field electroretinograms (ERGs) were recorded from wild-type (C57BL/6; Rpe65(+/+)) and Rpe65(-/-) mice at ages ranging from ∼1 month to 2 years. A physiologically based model of rod phototransduction activation was used to determine photoreceptor (P3) cell components of ERG photoresponses. A bipolar (P2) cell component was also derived. Photoreceptor and inner retinal thickness measurements were made by using optical coherence tomography in human RPE65-LCA.
RESULTS: Age-related declines in ERG photoreceptor and bipolar amplitudes were present in the Rpe65(-/-) mouse. The loss of photoresponse amplitude with age in the mutant mice paralleled reported losses of photoreceptor nuclear layer thickness over the same age range. Unexpectedly, the early activation phase of photoresponses in Rpe65(-/-) mice accelerated with age as amplitude decreased; this was not a feature of Rpe65(+/+) mice. Inner retinal dysfunction increased with age in the mutant mice. Human RPE65-LCA patients had retinal degeneration and loss of photoreceptors in the first decade of life. Unlike the mouse model, there were no examples of a normal photoreceptor complement. Abnormal thickening of the inner retina occurred with increasing loss of photoreceptors.
CONCLUSIONS: The differences in time course of murine and human RPE65-deficiency diseases suggests that preclinical efficacy testing of therapeutic modalities would be most informative when the murine disease becomes comparable to early human disease, toward the end of the first year of life in Rpe65(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484585     DOI: 10.1167/iovs.10-5559

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  16 in total

1.  Gene therapy for retinitis pigmentosa caused by MFRP mutations: human phenotype and preliminary proof of concept.

Authors:  Astra Dinculescu; Jackie Estreicher; Juan C Zenteno; Tomas S Aleman; Sharon B Schwartz; Wei Chieh Huang; Alejandro J Roman; Alexander Sumaroka; Qiuhong Li; Wen-Tao Deng; Seok-Hong Min; Vince A Chiodo; Andy Neeley; Xuan Liu; Xinhua Shu; Margarita Matias-Florentino; Beatriz Buentello-Volante; Sanford L Boye; Artur V Cideciyan; William W Hauswirth; Samuel G Jacobson
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

Review 2.  Chemistry of the retinoid (visual) cycle.

Authors:  Philip D Kiser; Marcin Golczak; Krzysztof Palczewski
Journal:  Chem Rev       Date:  2013-07-11       Impact factor: 60.622

3.  Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.

Authors:  Samuel G Jacobson; Artur V Cideciyan; Ramakrishna Ratnakaram; Elise Heon; Sharon B Schwartz; Alejandro J Roman; Marc C Peden; Tomas S Aleman; Sanford L Boye; Alexander Sumaroka; Thomas J Conlon; Roberto Calcedo; Ji-Jing Pang; Kirsten E Erger; Melani B Olivares; Cristina L Mullins; Malgorzata Swider; Shalesh Kaushal; William J Feuer; Alessandro Iannaccone; Gerald A Fishman; Edwin M Stone; Barry J Byrne; William W Hauswirth
Journal:  Arch Ophthalmol       Date:  2011-09-12

4.  Kinetic, energetic, and mechanical differences between dark-state rhodopsin and opsin.

Authors:  Shiho Kawamura; Moritz Gerstung; Alejandro T Colozo; Jonne Helenius; Akiko Maeda; Niko Beerenwinkel; Paul S-H Park; Daniel J Müller
Journal:  Structure       Date:  2013-02-21       Impact factor: 5.006

5.  Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy.

Authors:  Kristin L Gardiner; Artur V Cideciyan; Malgorzata Swider; Valérie L Dufour; Alexander Sumaroka; András M Komáromy; William W Hauswirth; Simone Iwabe; Samuel G Jacobson; William A Beltran; Gustavo D Aguirre
Journal:  Mol Ther       Date:  2019-09-03       Impact factor: 11.454

6.  Effects of aging and sensory loss on glial cells in mouse visual and auditory cortices.

Authors:  Marie-Ève Tremblay; Martha L Zettel; James R Ison; Paul D Allen; Ania K Majewska
Journal:  Glia       Date:  2012-01-05       Impact factor: 7.452

7.  Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.

Authors:  Artur V Cideciyan; Samuel G Jacobson; William A Beltran; Alexander Sumaroka; Malgorzata Swider; Simone Iwabe; Alejandro J Roman; Melani B Olivares; Sharon B Schwartz; András M Komáromy; William W Hauswirth; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

8.  Complementation test of Rpe65 knockout and tvrm148.

Authors:  Charles B Wright; Micah A Chrenek; Stephanie L Foster; Todd Duncan; T Michael Redmond; Machelle T Pardue; Jeffrey H Boatright; John M Nickerson
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-07-30       Impact factor: 4.799

9.  Retinal degeneration in mice expressing the constitutively active G90D rhodopsin mutant.

Authors:  Alejandro T Colozo; Sreelakshmi Vasudevan; Paul S-H Park
Journal:  Hum Mol Genet       Date:  2020-04-15       Impact factor: 6.150

Review 10.  Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.

Authors:  Albert M Maguire; Jean Bennett; Elena M Aleman; Bart P Leroy; Tomas S Aleman
Journal:  Mol Ther       Date:  2020-12-03       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.